Medical miracle: Health care innovation saves the world

by Laura Nelson Carney, equity investment analyst, Richmond Wolf, portfolio manager/investment analyst, Capital International Asset Management

COVID-19 vaccines were developed at record speed. Capital Group investment professionals discuss what these breakthroughs mean for the future of health care.We just witnessed a modern medical miracle.

Several drug developers brought COVID-19 vaccines from initial trials to people’s arms in less than a year. This lightning quick pace defied the expectations of health care professionals and saved countless lives. It was far faster than the development of any similar drug.

Bringing a vaccine to patients is a complex process typically measured in years or decades. Consider this: It took nearly 50 years of research and trials before Dr. Jonas Salk’s polio vaccine was introduced in 1955. More recently, vaccines for chickenpox and Ebola were each developed in about 42 years.

“It’s no exaggeration to call these COVID-19 vaccines one of the greatest scientific accomplishments in our lifetimes,” says health care analyst Laura Nelson Carney, who covers pharmaceutical and biotechnology companies in Europe and Asia and holds a doctorate in neuroscience. “What’s more, global manufacturing capacity is also larger than we would have thought possible a year ago: Thirteen billion doses of vaccine will be made this year.”

COVID-19 vaccines were developed at breakneck speed

Timeline of previous vaccine development (years)

Sources: Capital Group, NIAID, Our World in Data. Date ranges represent the approximate time between the year the pathogenic agent was first linked to the disease and the year that its vaccine became licensed in the U.S.

 

A truly global effort

In an age marked by global competition and rivalry, this historic achievement represented remarkable worldwide cooperation. Consider, for example, the vaccine introduced jointly by Pfizer and BioNTech, the first to receive U.S. approval for use.

“It was developed by a Turkish couple leading a German company partnered with a U.S. multinational led by a Greek immigrant with a Scandinavian chief scientific officer. That is a great affirmation of the global nature of innovation today.”

The broader effort also featured the cooperation of companies, governments and academia around the world. U.S. biotech firm Moderna partnered with a division of the U.S. National Institutes of Health (NIH) to develop a similar vaccine, and U.K. pharmaceutical giant AstraZeneca worked with Oxford University to make its version.

“It was developed by a Turkish couple leading a German company partnered with a U.S. multinational led by a Greek immigrant with a Scandinavian chief scientific officer. That is a great affirmation of the global nature of innovation today.”

Rich Wolf, portfolio manager/investment analyst

The U.S. (through Operation Warp Speed) and the European Union provided a level of funding that only governments can muster. “Billions of dollars of upfront government funding allowed companies to do many steps in parallel that they would normally do in sequence,” explains Nelson Carney.

Contributions from around the world pushed the pace of COVID-19 vaccine development

Contributions from around the world pushed the pace of COVID-19 vaccine development

Sources: Capital Group, Time, Moderna, Pfizer, U.S. Food and Drug Administration, World Health Organization.

 

These contributions, and others from around the world, proceeded at a breathless pace:

January 5, 2020 — Zhang Yongzhen, a Chinese virologist in Shanghai, and his team complete a mapping of the virus’s genome after 40 hours of around-the-clock work. When the human genome was first sequenced about two decades ago, it took a team of researchers at the NIH some 15 years at a cost of more than US$2.7 billion.

January 11, 2020 — Edward Holmes, a professor at the University of Sydney, places a call to Zhang while he is sitting on a runway in a Shanghai airport. Holmes asks for permission to publicly release the virus’s genome sequencing. Just before taking off, Zhang agrees, and Holmes publishes the sequencing on Virological.org.

January 13, 2020 — Using computer modeling, Cambridge, Massachusetts, biotech company Moderna, led by 35-year-old Hamilton Bennett, develops its first mRNA vaccine candidate. German biotech company BioNTech, led by Turkish researchers Ugur Sahin and Ozlem Tureci, model a vaccine in a similar time frame. Within a few months, BioNTech enters a partnership with Pfizer to develop, manufacture and distribute the vaccine.

January 21, 2020 — The first U.S. case of COVID-19 is identified in Washington State. By this time, the Moderna vaccine was being shipped to the NIH for the beginning of its Phase I clinical trial.

November 9, 2020 — The Pfizer-BioNTech vaccine is shown to be 94% effective against the virus. Pfizer applies for emergency use authorization of the vaccine in the U.S.

Mid-December 2020 — The U.S. FDA issues emergency use authorization (EUA) for the Pfizer vaccine, and a week later, the Moderna vaccine.

Will future drug development be this fast?

For scientists and companies alike, the obvious question is whether this breakneck pace can be repeated. While we may not see the same level of government spending on drug development as on COVID-19 vaccines, the speed of science has taken a great leap forward.

Advances in genetic analysis and the development of the world’s first mRNA vaccines are leading the way to a new era in medicine, says Wolf. These actions have the potential to be most disruptive in the area of immuno-oncology, or the treatment of various types of cancer.

”We can sequence tumors, compare their mutations to the map of the human genome and identify and match therapies to specific mutations,” Wolf says. Indeed, therapies derived from genetic testing have the potential to extend lives and generate billions of dollars in revenue for the companies that successfully develop them.

Advances in genetics and cell research are expanding the cancer drug pipeline

Advances in genetics and cell research are expanding the cancer drug pipeline

Source: Cancer Research Institute. Data as of May 2020. Immunotherapy is the artificial stimulation of the immune system to treat cancer. The seven categories of immunotherapy are based on the mechanism of actions to treat cancer.

 

Investment implications

1. Drug discovery goes global

The U.S. and Europe are not the only significant contributors to drug discovery. Chinese biotech company BeiGene recently got the first FDA approval for a blood cancer drug called Brukinsa, says Nelson Carney. Another company, HUTCHMED, will likely get an approval this year for its treatment targeting neuroendocrine tumors.

The role that China plays in the global pharma industry, both as an end-user market and as a source of globally relevant innovation, is only going to increase in the future.

2. The markets are potentially huge

For some types of cancer and other common ailments, the potential addressable market size can be enormous. “The first Chinese PD-1 inhibitor — the same category as Merck’s drug Keytruda — filed for approval in the U.S. only a few weeks ago,” says Nelson Carney. “This is potentially a US$50 billion market. The consensus peak sales for Merck’s drug are between US$25 billion and US$30 billion for just this drug. The patent doesn’t expire until 2028, but there are four other companies hot on its heels, also planning to file in the U.S.”

3. The 2020s will be the decade of health care

If the 2010s were the era for technology titans to lead markets and change the world, then the 2020s may well be the era when health care takes the lead. “There’s never been a more exciting time,” Wolf states. “It started with the sequencing of the human genome. We've developed and improved these tools over the last two decades, and now we’re using them not only to provide more accurate diagnostics, but to actually develop better therapies and to match therapies to those diagnostics.”

 

About

Laura Nelson Carney Equity investment analyst

Laura Nelson Carney is an equity investment analyst with six years of industry experience as of December 31, 2019. She holds a PhD in neurosciences from Imperial College London and a bachelor's degree in human biology from Stanford University.

Rich Wolf Portfolio manager/investment analyst

Rich Wolf is an equity portfolio manager with 23 years of investment industry experience. He also has equity investment analyst responsibilities covering U.S. medical technology companies and REITs. He holds a PhD from the California Institute of Technology and a bachelor's degree from Princeton.

 

 

 

 


Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.
Unless otherwise indicated, the investment professionals featured do not manage Capital Group‘s Canadian mutual funds.
References to particular companies or securities, if any, are included for informational or illustrative purposes only and should not be considered as an endorsement by Capital Group. Views expressed regarding a particular company, security, industry or market sector should not be considered an indication of trading intent of any investment funds or current holdings of any investment funds. These views should not be considered as investment advice nor should they be considered a recommendation to buy or sell.
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This information is intended to highlight issues and not be comprehensive or to provide advice. For informational purposes only; not intended to provide tax, legal or financial advice. We assume no liability for any inaccurate, delayed or incomplete information, nor for any actions taken in reliance thereon. The information contained herein has been supplied without verification by us and may be subject to change. Capital Group funds are available in Canada through registered dealers. For more information, please consult your financial and tax advisors for your individual situation.
Forward-looking statements are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied in any forward-looking statements made herein. We encourage you to consider these and other factors carefully before making any investment decisions and we urge you to avoid placing undue reliance on forward-looking statements.
The S&P 500 Composite Index (“Index”) is a product of S&P Dow Jones Indices LLC and/or its affiliates and has been licensed for use by Capital Group. Copyright © 2021 S&P Dow Jones Indices LLC, a division of S&P Global, and/or its affiliates. All rights reserved. Redistribution or reproduction in whole or in part are prohibited without written permission of S&P Dow Jones Indices LLC.
FTSE source: London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2021. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSE®" is a trade mark of the relevant LSE Group companies and is used by any other LSE Group company under licence. All rights in the FTSE Russell indices or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indices or data and no party may rely on any indices or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication. The index is unmanaged and cannot be invested in directly.
Bloomberg® is a trademark of Bloomberg Finance L.P. (collectively with its affiliates, "Bloomberg"). Barclays® is a trademark of Barclays Bank Plc (collectively with its affiliates, "Barclays"), used under licence. Neither Bloomberg nor Barclays approves or endorses this material, guarantees the accuracy or completeness of any information herein and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.
MSCI does not approve, review or produce reports published on this site, makes no express or implied warranties or representations and is not liable whatsoever for any data represented. You may not redistribute MSCI data or use it as a basis for other indices or investment products.
Capital believes the software and information from FactSet to be reliable. However, Capital cannot be responsible for inaccuracies, incomplete information or updating of the information furnished by FactSet. The information provided in this report is meant to give you an approximate account of the fund/manager's characteristics for the specified date. This information is not indicative of future Capital investment decisions and is not used as part of our investment decision-making process.
Indices are unmanaged and cannot be invested in directly. Returns represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment.
All Capital Group trademarks are owned by The Capital Group Companies, Inc. or an affiliated company in Canada, the U.S. and other countries. All other company names mentioned are the property of their respective companies.
Capital Group funds and Capital International Asset Management (Canada), Inc. are part of Capital Group, a global investment management firm originating in Los Angeles, California in 1931. Capital Group manages equity assets through three investment groups. These groups make investment and proxy voting decisions independently. Fixed income investment professionals provide fixed income research and investment management across the Capital organization; however, for securities with equity characteristics, they act solely on behalf of one of the three equity investment groups.

The Capital Group funds offered on this website are available only to Canadian residents.

Total
0
Shares
Previous Article

Building your advisory business, Part 3: Creating a system for success

Next Article

Ep. 66 Raise Your Average with Mark Noble, Executive VP, Horizons ETFs

Related Posts
Subscribe to AdvisorAnalyst.com notifications
Watch. Listen. Read. Raise your average.